Piper Jaffray weighs in on Sarepta's (SRPT +5.3%) earlier data update on its Phase IIb study of...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Piper Jaffray weighs in on Sarepta's (SRPT +5.3%) earlier data update on its Phase IIb study of on eteplirsen saying its very encouraged as there are no treatment options for DMD. The primary near-term value driver in the stock is SRPT's decision to file for accelerated approval later this month. Piper projects a 50/50 chance it will be able to file on existing data.